Scandinavian Journal of Gastroenterology
ISSN: 0036-5521 (Print) 1502-7708 (Online) Journal homepage: https://www.tandfonline.com/loi/igas20
Eosinophilic esophagitis in children: current
knowledge to open new horizons
Tommaso Alterio, Sabrina Cardile, Claire Trayers, Simona Valenti, Italia
Loddo, Roxana Mardare, Antonella Mosca & Valerio Nobili
To cite this article: Tommaso Alterio, Sabrina Cardile, Claire Trayers, Simona Valenti, Italia
Loddo, Roxana Mardare, Antonella Mosca & Valerio Nobili (2019): Eosinophilic esophagitis in
children: current knowledge to open new horizons, Scandinavian Journal of Gastroenterology, DOI:
10.1080/00365521.2019.1641214
To link to this article: https://doi.org/10.1080/00365521.2019.1641214
Published online: 26 Jul 2019.
Submit your article to this journal
Article views: 20
View related articles
View Crossmark data
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=igas20
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
https://doi.org/10.1080/00365521.2019.1641214
REVIEW
Eosinophilic esophagitis in children: current knowledge to open new horizons
Tommaso Alterioa, Sabrina Cardilea, Claire Trayersb, Simona Valentic, Italia Loddod, Roxana Mardaree, Antonella
Moscaa and Valerio Nobilia,f
a
” Children’s Hospital, Rome, Italy; bDepartment of Paediatric and
Hepatology, Gastroenterology and Nutrition Unit, IRCCS “Bambino Gesu
Perinatal Pathology, Cambridge University Hospitals (CUH), Addenbrooke’s Hospital, Cambridge, UK; cDepartment of Pediatrics, University of
Messina, Messina, Italy; dDepartment of Laboratory Medicine and Advanced Biotechnologies, Mediterranean Institute for Transplantation
and Advanced Specialized Therapies (ISMETT) – IRCCS, Palermo, Italy; eDepartment of Pediatrics, Cambridge University Hospitals (CUH),
Addenbrookes Hospital, Cambridge, UK; fDepartment of Pediatrics, University “La Sapienza”, Rome, Italy
ABSTRACT
ARTICLE HISTORY
Eosinophilic Esophagitis (EoE) is a chronic immune/antigen-mediated condition which is also driven by
genetic and environmental factors. It has been deeply investigated over the last years and its incidence is widely increasing in childhood. Although atopic diseases are closely linked with EoE, it does
not recognize a classical IgE-mediate immune pathogenesis but it is rather a T helper type 2 inflammatory process. Familial clustering supports genetic predisposition in EoE and recent advances in understanding the genetic basis for EoE may eventually translate into targeted management of the disease.
EoE diagnosis is based on clinical symptoms, micro, and macroscopic findings along with exclusion of
gastroesophageal reflux disease (GERD) evidence. Management of the disease encompasses both dietary and pharmacological solutions that need to be specifically targeted on patients’ history, clinical
symptoms, and diagnostic evaluations. New therapies, currently not available in children, may represent the basis for future therapeutic options in the next years.
Received 2 December 2018
Revised 30 June 2019
Accepted 2 July 2019
KEYWORDS
Gastrointestinal diseases;
gastroesophageal reflux
disease; esophageal
diseases; eosinophilic
disorders; children
Introduction
Definition
Eosinophilic esophagitis (EoE) is a relatively new diagnostic
entity, having only been first reported in 1977 [1,2]. Since then
it has become increasingly recognized as a cause of morbidity
for children and adults. Due to the overlap in clinical features
with common gastro-esophageal reflux disease (GERD), there is
additional pressure on tertiary pediatric gastroenterology services to perform an endoscopy to exclude the diagnosis.
We carried out a review including the most pertinent
manuscripts on “Pediatric Eosinophilic Esophagitis” present on
PubMed (https://www.ncbi.nlm.nih.gov/pubmed/) over the last
25 years (1993–2018); papers were selected from RCTs, case
reports, reviews, systematic reviews, cohort and case–control
studies, and observational studies. Researched terms were
“pediatric eosinophilic esophagitis” [all fields]; “eosinophilic
esophagitis” and “children” [all fields]; “pediatric eosinophilic
esophagitis” and “management” [all fields]; “pediatric eosinophilic esophagitis” and “treatment” [all fields]; “pediatric
eosinophilic esophagitis” and “therapy” [all fields]; “pediatric
eosinophilic esophagitis” and “diet” [all fields]; “pediatric
eosinophilic esophagitis” and “probiotics” [all fields];
“esophageal eosinophilia” [all fields]; “pediatric GERD” [all
fields]; “gastroesophageal reflux” and “children” [all fields].
This review aims to provide an update with recent advances on EoE in children and reflect on what remains unclear
in this challenging condition.
According to the 2014 ESPGHAN Guidelines, EoE is defined
as a chronic immune/antigen-mediated disorder of the
esophagus with typical features represented by esophageal
dysfunction and histologic finding of eosinophil-predominant
inflammation [3].
Furuta et al. included in the definition of the disease the
presence of esophageal and/or upper gastrointestinal (GI)
tract symptoms in association with esophageal mucosal finding of > 15 eosinophils in 1 high-power field in one or more
biopsy specimens along with the exclusion of GERD evidenced by lack of responsiveness to high-dose proton pump
inhibition (PPI) (up to 2 mg/kg/day) or normal pH monitoring
study of the distal esophagus [4]. However, recent evidence
in the adult setting have considered PPI therapy as a proper
treatment for EOE rather than a diagnostic tool, therefore in
the adult guidelines, PPI trial has not been included in the
definition anymore [5].
CONTACT Sabrina Cardile
sabrina.cardile@opbg.net
Sant’Onofrio 4, Rome 00165, Italy
ß 2019 Informa UK Limited, trading as Taylor & Francis Group
Epidemiology
The incidence of EoE in children has been investigated by
several studies with high variability in estimates. It is an
emerging disease where reported incidence is increasing,
though it is unclear to what extent this reflects increased
diagnosis, and currently varies widely from 1 to 20 new cases
Hepatology, Gastroenterology and Nutrition Unit, Bambino Ges
u Children’s Hospital, Piazza
2
T. ALTERIO ET AL.
per 100,000 inhabitants per year. Although all ages can be
affected, the majority of patients present in childhood, adolescence, and adulthood under the age of 50 with a peak at
30–50 years [4–6]. Males are more commonly affected than
females (M/F ratio of about 3:1) [4]. A recent study reported
a prevalence between 1 and 5 per 100,000 persons in the
United States and Europe [7]. Another study suggests that
EoE prevalence estimates vary from region to region tending
to be on the same order of magnitude in Western Europe,
North America, and Australia though much lower in Japan
and China. Interestingly, there are no reports from subSaharan Africa and India despite similarities in clinical presentation and molecular features, indicating an opportunity for
future study of etiologic mechanisms that focus on environmental factors [8]. In a recent meta-analysis, data reported a
higher prevalence in adults (43.4/100,000 (95% confidence
interval (CI) 22.5–71.2)) than in children (29.5/100,000 (95%
CI 17.5–44.7) [9–11]. The majority of epidemiological data on
EoE originates from North America and Europe. The condition has been described in patients with a variety of ethnic
backgrounds, but it remains to be established whether ethnic predilection accounts for the differences described above.
Socioeconomic distribution and seasonal variation in EoE
have not been systematically examined [4].
Etiology
EoE pathogenesis is a highly active area of research. It is an
immune-mediated inflammatory disorder with genetic and
environmental drivers, including microbial exposure [11].
Between 50% and 80% of patients with EoE have a family or
personal history of atopic diseases such as food allergy,
asthma and allergic rhinitis, and the evidence indicates that
it has a familial association, with nearly 10% of parents of
EoE patients having a history of esophageal strictures and
about 8% having biopsy-proven EoE [9,12]. However, unlike
these conditions, EoE does not seem to be a classic IgE
mediated immune response rather it is a T helper type 2 cell
(Th2) predominant inflammatory process triggered by allergens. Adaptive T cell immunity, driven by Th2 cells and
involving IL-13, IL-5, and IL-15 expression, appears to play a
major role in the pathogenesis of EoE [13]. Moreover, the
epithelial barrier abnormalities in EoE are caused by a combination of genetic, environmental and immunological factors, and may allow enhanced allergen penetration and
systemic allergen sensitization [14]. Candidate gene like
CCL26 (Eotaxin-3), FLG (Filaggrin), TSLP (Thymic Stromal
Lymphopoietin) and TSLP receptor (TSLPR) gene, CAPN14
and ANKRD27 gene, and other are considered important in
the pathogenesis of the disease (Table 1) [12,15–17]; and
these recent advances in understanding the genetic basis for
EoE may eventually translate into targeted management of
the disease [18]. Another important factor in the pathogenesis of EoE is considered gut microbiota. Gut microbiota
composition embraces a wide-ranging of bacteria divided in
species and strain which differ throughout the GI tract with
Bacteroidetes and Firmicutes representing the largest phyla
compared to the relatively less common Proteonacteria,
Acinobacteria, Fusobacteria and Verrucomicrobia. Gut microbiota contributes to the stimulation and maturation of the
immune system; therefore, a disequilibrium in the gut flora
may alter these processes [19].
Recently, a group from Philadelphia [20] used 16S rRNA
gene sequencing showed a distinctive microbiota signature
in active EoE compared to non-EoE controls with more abundant Proteobacteria in the EoE cohort while Firmicutes in
non-EoE controls. Another study [21] found that bacterial
load was increased in both EoE and GERD patients compared
to normal subjects, and EoE patients with active inflammation showed an increase in Hemophilus compared to control
subjects with a normal esophagus or GERD. Consistent with
Benitez et al. [20], the microbiota in untreated EoE patients
showed a shift from a Gram-positive population (Firmicutes)
to an increase in Gram-negative bacteria (Proteobacteria).
Moreover, dysregulation of the brain–gut–microbiota axis,
which is the cross-talk between the central nervous system
(CNS), the gastrointestinal tract and its microbiota, may play
a role in the pathophysiology of EoE as it has been already
associated with several GI diseases such as inflammatory
bowel disease, food antigen-related adverse response, peptic
ulcer, and GERD [19].
Overall, it is established that there is a specific microbiome signature associated with EoE though it appears to be
less dietary responsive than colonic microbes. It is yet to be
established whether manipulation of the microbiome will
be a clinical strategy as it has been already described in
functional gastrointestinal disorders (FIGDs) where probiotics
were successfully used for prevention and treatment [22,23].
Macroscopic and microscopic findings
Oesophagogastroduodenoscopy (OGD) with multiple esophageal biopsies is considered the gold standard diagnostic
technique. Biopsies are performed throughout the esophagus
as well as gastroduodenal tract to rule out concomitant
framework eosinophilic gastroenteropathy.
According to Shah et al., at least three esophageal biopsy
specimens taken from different parts of the esophagus are
needed to achieve a diagnosis of EoE in 97% of patients DA
QUI IN POI 22 diventa 24 [3,24]. According to Gonsalves
et al. [25], one biopsy specimen has a sensitivity of only 55%,
whereas five biopsies increase this to 100%. To maximize
diagnostic sensitivity, it is, therefore, recommended that at
least 2–4 biopsies should be taken from both the proximal
and distal esophagus [26]. It is useful to take at least 4–5
biopsies (1–2 per portion esophageal) to reach a sensitivity
diagnostic up to 90–95% [4]. Several endoscopic features
have been described in esophagus of patients with EoE such
as longitudinal furrowing, friability, edema, longitudinal
shearing, narrow caliber esophagus, esophageal rings, a
thickened and sometimes pale mucosa with linear furrows
and white exudates “cr^epe paper mucosa,” and less often,
narrowing of the caliber of the esophagus [4]. These features
are associated with changes in motility and esophageal peristalsis, which are thought to give rise to dysphagia. Although
none of these can be classified as pathognomonic features
No
No
TSLP
TSLPR
STAT6
EMSY
CAPN14
ANKRD27
5q22.1
Xp22.3; Yp11.3
12q13.3
11q13.5
2p23.1
19q13.11
Ankyrin Repeat Domaincontaining protein 27
rs3815700
Member of the caplain family (intracellular
calcium-activated cysteine protease)
Regulate endosome dynamics and Regulates
the proper trafficking of melanogenic
enzymes to melanosomes in melanocytes
rs77569859
Allergic sensitization, multiple
allergic/inflammatory phenotypes
Transcriptional regulator
rs55646091
Allergic sensitization, total serum IgE
levels and eosinophilia
Signal transducer and activator of
transcription
rs36133495
rs3806932
Thymic Stromal
Lymphoprotein
Thymic Stromal
Lymphoprotein
Receptor
Signal Transducer and
Activator of
Transcription 6
Chromosome 11 Open
Reading Frame
30 (c11orf30)
Calpain 14
rs324011
Atopic dermatitis
Allergic skin inflammation
Atopic dermatitis
rs2302009
Eotaxin-3
CCL26
7q11.2
Filaggrin
Gene
FLG
Locus
1q21.3
Table 1. Genetics of EoE (GWAS-discovered loci).
Product
SNP with effect allele
Loss-of-function variants
Function
The major protein component of the
keratohyalin granules of mammalian
epidermis with a role in skin
barrier function
Chemokine inducing eosinophils and
basophils migration
B cell-stimulating factors (increased
basophil response)
Member of the type I cytokine
receptor family
Susceptibility to other
allergic disorders
Atopic dermatitis and eczema
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
3
of EoE, one or more of the above endoscopic aspects may
be strongly suggestive of this disease, in the presence of
clinical symptoms. Conversely, some studies have reported
that an absence of endoscopic alterations does not exclude
the diagnosis of EoE [4]. Stenosis or reduction of the esophageal caliber is more serious and advanced lesions, secondary
to eosinophilic prevalent inflammation, collagen deposition
and resulting fibrosis. Mucosal erosions or ulceration are not
characteristic of EoE and are more indicative for GERD,
Crohn’s disease, or other diagnoses [3]. The main microscopic
features are represented by dense eosinophilia of the
esophageal mucosa, basal zone hyperplasia, lamina propria
fibrosis, and sometimes eosinophilic microabscesses
(Figure 1) [27]. The presence of an increased number of eosinophils in the esophageal epithelium which is a mucosa that
is typically devoid of eosinophils is the histologic hallmark of
EoE [7]. Available data indicate that a number of sinopeosinophils per field represent a histological diagnosis of EoE in
correlation with the clinical picture [3]. Other microscopic
features, but not pathognomonic, include an aggregate of
eosinophils or microabscess and eosinophil layering along
the luminal surface, dilated intracellular spaces, rete-peg
elongation, basal-cell hyperplasia and numbers of inflammatory cells including lymphocytes, mast cells, and basophils
[7]. It should be noted, however, that the size of a highpower field has not been standardized. This may alter the
sensitivity/specificity of the lower threshold of diagnosis at
15 eos/per field. Furthermore, it should be considered that
diagnostic biopsies are predominantly epithelial and may
underestimate deeper disease activity as eosinophil recruitment begins within the subepithelial compartment [3].
Clinical symptoms
Clinical symptoms of EoE vary with age. Infants and toddlers
present with a range of feeding difficulties including vomiting, regurgitation, and food refusal, sometimes resulting in
failure to thrive. During childhood, there are more specific
symptoms: vomiting and/or abdominal or retrosternal pain,
therefore, GERD-like symptoms. During adolescence, the
most frequent symptoms are also GERD symptoms, though
dysphagia and food impaction are more prominent in EoE
[3,28]. Peripheral eosinophilia (> 700 cells/mm3) can be
found in children with EoE [3,29]. Furthermore, in children
with EoE, specific immunoglobulin E (IgE) antibodies to foods
which may (or may not) be the causative foods of the disease have been reported [3,27].
Differential diagnosis
Many diseases associated with esophageal eosinophilia, such
as infectious esophagitis, esophageal achalasia, celiac disease,
Crohn’s disease, connective tissue disorders, graft-versus-host
disease, drug hypersensitivity, and hypereosinophilic syndromes, should be excluded [4,26]. The main differential
diagnosis for symptoms and histopathological findings is
GERD (Table 2). However, it is not clear how to differentiate
reliably EoE from GERD. The diagnosis of EoE should be
4
T. ALTERIO ET AL.
Figure 1. A and B: EoE histology – Superficial biopsy of oesophageal squamous epithelium in which there is a prominent eosinophilic infiltrate and patchy basal
cell hyperplasia.Images gently given by Department of Pediatric and Perinatal Pathology, Addenbrooke’s Hospital, Cambridge, UK.Patient consent for the use of
images for teaching purpose given at the time of procedure.
Table 2. Differences between EoE and GERD.
History of atopy
Predominance m/f
Etiology
Predominant symptoms
Macroscopic findings
Hystology
Diagnostic markers
Diagnostic tests
Therapy
EOE
Common
3:1
Immune-mediated inflammatory disorder
Dysphagia
Food impaction
GERD
Esophageal rings
Edema
Thickened mucosa
Exudates furrows
Narrowing of the caliber of the esophagus
Strictures
Normal findings (uncommon, <10%)
15 eosinophils per hpf (usually panesophageal)
Basal zone hyperplasia
Lamina propria fibrosis
Eosinophilic microabcesses
Uncommon
1:1
Acid reflux
Regurgitation
Retrosternal pain
Heartburn
Erosions
Ulcerations
Normal findings (common)
< 15 eosinophils per hpf (usually limited to distal esophagus)
Peripheral eosinophilia (700 cells/mm3)
Specific IgE to food allergens
Eosinophil-derived proteins in luminal secretions
Upper gastrointestinal endoscopy
Unknown
PPI
Elimination diet
Steroids
Antiacid drugs
PPI
H2 receptor blockers
Intraluminal impedance and esophageal pH monitoring
Esophageal manometry
Upper gastrointestinal endoscopy
EOE: eosinophilic esophagitis; GERD: gastro-esophageal reflux disease; hpf: high-power field; IgE: immunoglobulin; PPI: proton-pump inhibitors.
based on a combination of symptoms and histologic and
endoscopic findings bearing in mind that no single feature is
sufficient to establish a definitive diagnosis [30].
In the first description of the disease [31], GERD and EoE
were considered mutually exclusive disorders and the first
guidelines for diagnosis and management of EoE suggested
that patient with esophageal eosinophilia who responded to
PPIs or had abnormal acid reflux suffered from GERD instead
of EoE [4,32]; however, the distinction is now felt to be less
dichotomous. The inflammatory process of EoE may lead to
a hypersensitivity to acid exposure, even in the absence of
erosions, comparable with non-erosive reflux disease [3]. EoE
and GERD are not mutually exclusive or may even exacerbate
each other.
Selection of which children to perform endoscopy on is
challenging and, currently, there are no specific biomarkers
in routine practice. This is a field of active research and a
recent study reported that the measurement of eosinophilderived proteins in luminal secretions could be used to distinguish children with EoE from those with GERD [33].
Although endoscopy plays a key role in the diagnosis of
GERD, if the clinical assessment is suggestive enough then
empiric PPI therapy may be used. However, endoscopy it is
required for diagnostic uncertainty, “red flag” symptoms (e.g.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
dysphagia), when symptoms do not respond to empiric PPI
therapy, and before starting corticosteroids [34].
Management
The target of EoE’s therapy is the achievement and maintenance of clinical and histological remission and also prevents
iatrogenic damage caused by adverse effects related to
pharmacological therapy and nutritional deficiencies caused
by a long-term elimination diet [32,35]. The confirmation of
remission can be done only be formally confirmed through
an endoscopic revaluation before food reintroduction or
drug titration. All intervention should be individually tailored:
atopic patients mostly benefit from diet elimination, whereas
non-atopic patients benefit most from steroid therapy [3,35].
Empiric treatment
According to the ESPGHAN Guidelines [3], in symptomatic
children with histological findings of esophageal eosinophilia,
a trial of PPIs is recommended for 8 weeks. A second OGD
should be performed under PPI therapy in all children, even
if symptoms are resolved. If histology is still suggestive of
EoE and other causes of esophageal eosinophilia are unlikely,
then the diagnosis of EoE can be made. If the first endoscopy is performed after an adequate trial of PPI, the diagnosis of EoE can also be made and specific treatment for
EoE initiated.
Dietary solutions
There are three types of the elimination diet for patients
with EoE: amino acid-based formulas (AAF), targeted elimination diet (TED), and empiric elimination diet (EED).
Although there are no randomized controlled trials, the
available literature to date seems to assert that AAF is the
most successful intervention [35]. AAF consists of food allergens complete removal, replaced with a hypoallergenic milk
formula based on amino acids [36]. However, the use of this
formula has advantages and disadvantages. In children, the
resolution of characteristic symptoms such as vomiting,
abdominal pain and dysphagia usually subsides between 8 d
and 2 weeks from the introduction of hypoallergenic formula
while the histological resolution has been reported in 4
weeks [37–39].
The use of AAF is, however, burdened by excessive cost
and the frequent need for nasogastric tube delivery because
of low palatability. To date, AAF is restricted to children with
multiple food allergies or who does not respond to a strict
elimination diet [35].
TED is indicated in those patients who have a suggestive
history of food allergies with a positive test such as Skin
Prick Tests (SPTs) and Allergy Patch Test (APT). Some EoE
patients have multiple food allergies and it is sometimes difficult to identify the responsible food allergen through the
common skin tests; often it is possible that the food allergen
tested positive to the SPT or APT is not responsible for the
disease. This can lead to the unnecessary elimination of
5
foods [35]. However, it should be highlighted that an elimination diet based on a combination of SPT and APT was
reported to achieve resolution of both symptoms and histological abnormalities in 77% of children with EoE [40].
The most common foods tested with SPT and APT include
milk protein, egg, peanuts, soy, a variety of grains (wheat,
rice, corn, rye, oats, and barley), meat, vegetables, and fruits.
Due to the TH2-nature of the inflammatory activity, even
extensive allergy testing may return false-negative results,
potentially leading to incomplete elimination diet of offending food antigens if these results are taken in isolation [3].
In children with gastrointestinal manifestations of cow’smilk protein (CMP) allergy, specific IgE tests results are commonly negative without excluding the diagnosis of CMP
allergy [41,42]. CMP is a common food antigen and the leading cause of food allergy in infants and children younger
than 3 years [43,44]; some studies suggested that it is often
avoided from the diet in this age group, regardless of the
results of specific IgE or SPT/APT testing.
Another strategy for EoE is represented by EED, which is
based on the elimination from the diet of foods that, regardless of sensitization, are strongly correlated with EoE (soy,
eggs, wheat, peanuts, fish, and shell-fish). This strategy in
some studies showed a clinical and histological improvement
in 74% of children [45]. Support from a pediatric nutritionist
is essential for all significant elimination diets.
Diet efficacy
When children are treated with AAF, the second-look-endoscopy should be performed at 4 weeks after the resolution of
symptoms. In cases of TED or EED, resolution of symptoms is
usually delayed and repeating endoscopy should be performed at 8–12 weeks from the beginning of treatment strategy. In the case of histological remission, food reintroduction
should be commenced with the least allergenic foods [40].
Some centers suggest a more invasive approach consisting of periodic repetition of endoscopies in order to ensure
both clinical and histological resolution of the disease and
also an endoscopy after the reintroduction of foods [35].
Drug therapy
Proton pump inhibitors (PPI)
Until recently, PPI has been considered a diagnostic-tool in
the differential diagnosis between EoE and GERD. Lack of
responsiveness to high-dose PPI along with clinical and
esophageal (micro- and macroscopic) findings exclude GERDassociated esophagitis and confirm EoE [4]. Over the last few
years, a new entity known as “proton pump inhibitor-responsive esophageal eosinophilia” (PPI-REE) has been used for
patients who meet criteria for EoE but are also responsive to
PPI therapy [6,46]. Despite this, recent evidences state that,
in adults, PPI-REE and EoE are indistinguishable from one
other, even at genetic levels; therefore, PPI therapy should
be considered as a therapeutic agent rather than a diagnostic tool; however, it still remains unknown whether the
esophageal immune response of patients with EoE who
6
T. ALTERIO ET AL.
respond to PPI therapy is triggered by GERD, food allergens
or both [6]. Although this has been endorsed in adults,
promising results also come from recent pediatric studies,
with 70% of children with PPI-responsive EoE in histological
and clinical remission after 1-year follow-up [47]. However,
PPI-therapy should be still considered a diagnostic tool in
children as the latest guidelines on EoE state that further
studies are required to show whether the diagnosis of EoE
can be assumed without PPI treatment, this because the
proportion of children with esophageal eosinophil count of
15 eos/hpf that are responsive to PPI is unclear because
only retrospective data on selected patients are currently
available [3].
Steroids
Systemic and topical corticosteroids are both highly efficacious in inducing clinical and histological remission, even if
systemic steroids are burdened with many side effects
(hyperphagia, weight gain, and/or cushingoid features), and,
for this reason, not recommended [6]. Studies show that clinical remission is achieved after 1 week from the use of oral
steroids and histological remission after 4 weeks [48]. Due to
the potential adverse effects of systemic steroids yet excellent results on remission, their relative benefits and disadvantages should be discussed in the case with parents [35]. The
use of systemic corticosteroids is indicated when the patient
has severe dysphagia, dehydration, weight loss, or esophageal strictures. In all other cases, topical steroids are the first
line of treatment for EoE. The dose of prednisone for the
resolution of symptoms and for the regression of histological
alterations is 1–2 mg/kg/d with a maximum dose of
40–60 mg [35]. Topical fluticasone has given positive results
on histologic remission without difference between resolution of symptoms, relapse, or timing of relapse [49].
Fluticasone propionate and the oral viscous budesonide
(OVB) are the most commonly used topical steroids.
Fluticasone propionate in the form of oral spray is recommended at a dosage of 88–440 mcg from two times to four
times per day [26]. OVB in the form of preparation for inhalation is recommended at a dosage of 1 mg per day for children < 10 years and 2 mg per day for children > 10 years [26].
Titration of these drugs should be commenced after confirmation of histological and clinical resolution of symptoms
with a subsequent endoscopy at 4–12 weeks of drugs introduction [3].
Other therapies
Other drug therapies such as montelukast, a leukotriene
receptor antagonist, biologic agents, immunomodulators
such us Azathioprine (AZA) and 6-Mercaptopurine (6-MP)
and sodium cromoglycate are not recommended for treating
pediatric EoE at this time until further data is available [1].
Montelukast has been studied for the treatment of EoE
but results are conflicting [50]. In 2017, an RCT compared
maintenance therapy with montelukast versus placebo in a
patient who was topical steroids responders and reported no
differences in symptoms recurrence between groups [50,51].
Infliximab and Omalizumab targeting tumor necrosis factor
and IgE, respectively, have not been effective in treating EoE
[52]. Mepolizumab and Reslizumab (both IL-5 blockers) partially reduced esophageal eosinophilia but did not ameliorate
esophageal fibrosis and demonstrated a poor symptom
response. Reslizumab improved the histologic response but
symptom response was no better than placebo [52,53]. AZA
and 6-MP have been studied in a small court of patients
who were refractory to steroids and after an initial response,
they relapsed with recurrent eosinophilia when treatment
was stopped [50,54].
Oral viscous sodium cromoglycate (cromolyn sodium) is a
non-steroidal anti-inflammatory, mast cell stabilizer agent. A
recent randomized, double-blinded, placebo-controlled trial
conducted in a cohort of sixteen pediatric patients did not
significantly decrease esophageal eosinophilia, neither symptoms more than placebo and only led to complete resolution
in one patient [55].
Refractory disease
Refractory EoE can be defined as persistent eosinophilia with
incomplete symptom resolution and persistent endoscopic
findings after a PPI trial and after topical steroid treatment or
dietary elimination [50]. Depending on the treatment modality, non-response to topical steroid or dietary elimination in
EoE occurs in up to 50% of patients. Reasons for nonresponding EoE may be non-adherence to therapy, incorrect
dosing, errors in formulation or administration, ongoing allergen or food trigger exposure, inadequate dietary elimination
and validity of original diagnosis [50]. In some cases, patients
may be refractory to treatment because they have a stricture
or a small-caliber esophagus which will likely need a series
of dilatation in order to achieve an esophageal diameter that
allows reasonable oral intake [30].
Management of refractory EoE consists in first maximizing
the initial treatment and then to switch from topical steroids
to dietary elimination or vice versa. If there is still no
response, alternative treatments could be considered in
selected patients including custom topical steroids, elemental
formula, a short course of prednisone, immunomodulators,
or montelukast. Even if combination therapy with corticosteroids and elimination diet has not been tested in a randomized, prospective manner, combination therapy may be
considered as an option [50,52,56].
Conclusion
Pediatric EoE is increasingly becoming such as interesting
field of study due to its worldwide diffusion. EoE pathogenesis is not still completely understood therefore further studies need to investigate whether immunological factors,
genetics, and possibly the microbiota analysis may add
knowledge to this complex multifactorial disease. Diagnosis
has to take into account both clinical symptoms, macroscopic, and microscopic esophageal findings; however, the
selection of children who need endoscopy still remains challenging for the clinicians. Treatment is helped by allergy
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
tests (SPT/APT) and encompasses dietary solutions and/or
medications such as PPI and steroids. The administration of
PPI is conflicting as considered a diagnostic tool in the latest
pediatric guidelines and, controversially, a proper treatment
in the adult ones given the high-rate of response in EoE
patients treated with PPI. Topical steroids are considered the
first line of pharmacological treatment with excellent results,
oral steroids are, instead, indicated in severe disease or in
patients not responding to topical steroids, due to their collateral side effects. Further RCTs will need to clarify whether
emerging therapies, especially biologic agents, may be considered useful in a pediatric setting. Refractory EoE is common and usually needs therapy adjustment and reevaluation
of patient history and risk factors. Pediatric EoE is a relatively
new clinical entity which still needs research to cast light on
its causes and pathophysiology in order to clarify and
address current unmet needs routinely faced by clinicians in
diagnosis and management of the disease.
Acknowledgments
The authors thank Dr J. P. Mann (Department of Pediatrics, University of
Cambridge, UK) for the contribution given in the final editing of
the review.
Disclosure statement
[11]
[12]
[13]
[14]
[15]
[16]
[17]
[18]
[19]
[20]
[21]
[22]
[23]
All authors declare that they have no conflict of interest. The data presented, the statements made, and the views expressed are solely the
responsibility of the authors.
[24]
References
[1]
[2]
[3]
[4]
[5]
[6]
[7]
[8]
[9]
[10]
Dobbins JW, Sheahan DG, Behar J. Eosinophilic gastroenteritis
with esophageal involvement. Gastroenterology. 1977;72:
1312–1316.
Landres RT, Kuster GG, Strum WB. Eosinophilic esophagitis in a
patient with vigorous achalasia. Gastroenterology. 1978;74:
1298–1301.
Papadopoulou A, Koletzko S, Heuschkel R, et al. Management
guidelines of eosinophilic esophagitis in childhood. J Pediatr
Gastroenterol Nutr. 2014;58:107–118.
Furuta GT, Liacouras CA, Collins MH, et al. Eosinophilic esophagitis in children and adults: a systematic review and consensus
recommendations for diagnosis and treatment. Gastroenterology.
2007;133:1342–1363.
Lucendo AJ, Molina-Infante J, Arias A, et al. Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults.
United Eur Gastroenterol J. 2017;5:335–358.
Ruffner MA, Spergel JM. Eosinophilic esophagitis in children. Curr
Allergy Asthma Rep. 2017;17:54.
Furuta GT, Katzka DA. Eosinophilic esophagitis. N Engl J Med.
2015;373:1640–1648.
Dellon ES, Hirano I. Epidemiology and natural history of eosinophilic esophagitis. Gastroenterology. 2018;154:319–332.
Chen JW, Kao JY. Eosinophilic esophagitis: update on management and controversies. BMJ. 2017;359:j4482.
Perez-Martınez I, Tenıas JM, et al. Systematic review with
Arias A,
meta-analysis: the incidence and prevalence of eosinophilic
oesophagitis in children and adults in population-based studies.
Aliment Pharmacol Ther. 2016;359:3–15.
[25]
[26]
[27]
[28]
[29]
[30]
[31]
[32]
[33]
[34]
7
D’Alessandro A, Esposito D, Pesce M, et al. Eosinophilic esophagitis: from pathophysiology to treatment. World J Gastrointest
Pathophysiol. 2015;6:150–158.
Spergel JM. New genetic links in eosinophilic esophagitis.
Genome Med. 2010;2:60.
Niranjan R, Rajavelu P, Ventateshaiah SU, et al. Involvement of
interleukin-18 in the pathogenesis of human eosinophilic esophagitis. Clin Immunol. 2015;157:103–113.
Oyoshi MK. Recent research advances in eosinophilic esophagitis.
Curr Opin Pediatr. 2015;27:741–747.
Kottyan LC, Davis BP, Sherrill JD, et al. Genome-wide association
analysis of eosinophilic esophagitis provides insight into the tissue specificity of this allergic disease. Nat Genet. 2014;46:
895–900.
Sleiman PM, Wang ML, Cianferoni A, et al. GWAS identifies four
novel eosinophilic esophagitis loci. Nat Commun. 2014;5:5593.
O’Shea KM, Aceves SS, Dellon ES, et al. Pathophysiology of
eosinophilic esophagitis. Gastroenterology. 2018;154:333–345.
Cianferoni A, Spergel JM. From genetics to treatment of eosinophilic esophagitis. Curr Opin Allergy Clin Immunol. 2015;15:
417–425.
Indrio F, Riezzo G, Raimondi F, et al. Microbiota involvement in
the Gut–Brain axis. J Pediatr Gastroenterol Nutr. 2013;57:11–15.
Benitez J, Hoffmann C, Amanda BM, et al. Inflammation-associated microbiota in pediatric eosinophilic esophagitis.
Microbiome. 2015;3:23.
Harris JK, Fang R, Wagner BD, et al. Esophageal microbiome in
eosinophilic esophagitis. PLoS One. 2015;10:e0128346.
Indrio F, Di Mauro A, Riezzo G, et al. Prevention of functional
gastrointestinal disorders in neonates: clinical and socioeconomic
impact. Benef Microbes. 2015;6:195–198.
Baldassarre ME, Di Mauro A, Tafuri S, et al. Effectiveness and
safety of a probiotic-mixture for the treatment of infantile colic: a
double-blind, randomized, placebo-controlled clinical trial with
fecal real-time PCR and NMR-based metabolomics analysis.
Nutrients. 2018;10:195.
Shah A, Kagalwalla AF, Gonsalves N, et al. Histopathologic variability in children with eosinophilic esophagitis. Am J
Gastroenterol. 2009;104:716–721.
Gonsalves N, Policarpio-Nicolas M, Zhang Q, et al.
Histopathologic variability and endoscopic correlates in adults
with eosinophilic esophagitis. Gastrointest Endosc. 2006;64:
313–319.
Liacouras CA, Furuta GT, Hirano I, et al. Eosinophilic esophagitis:
updated consensus recommendations for children and adults. J
Allergy Clin Immunol. 2011;128:3–20.
DeBrosse CW, Collins MH, Buckmeier Butz BK, et al. Identification,
epidemiology, and chronicity of pediatric esophageal eosinophilia. J Allergy Clin Immunol. 2010;126:112–916.
Spergel JM, Brown-Whitehorn TF, Beausoleil JL, et al. 14 Years of
eosinophilic esophagitis: clinical features and prognosis. J Pediatr
Gastroenterol Nutr. 2009;48:30–36.
Sant’Anna AM, Rolland S, Fournet JC, et al. Eosinophilic esophagitis in children: symptoms, histology and pH probe results. J
Pediatr Gastroenterol Nutr. 2004;39:373–377.
Straumann A, Katzka DA. Diagnosis and treatment of eosinophilic
esophagitis. Gastroenterology. 2018;154:346–359.
Attwood SEA, Smyrk TC, Demeester TR, et al. Esophageal eosinophilia with dysphagia – a distinct clinicopathologic syndrome.
Digest Dis Sci. 1993;38:109–116.
Munoz-Persy M, Lucendo AJ. Treatment of eosinophilic esophagitis in the pediatric patient: an evidence-based approach. Eur J
Pediatr. 2018;177:649–663.
Furuta GT, Kagalwalla AF, Lee JJ, et al. The oesophageal string
test: a novel, minimally invasive method measures mucosal
inflammation in eosinophilic oesophagitis. Gut. 2013;62:
1395–1405.
Prakash Gyawali C, Kahrilas PJ, Savarino E, et al. Modern diagnosis of GERD: the Lyon Consensus. Gut. 2018;1136:1–12.
8
T. ALTERIO ET AL.
[35]
Papadopoulou A, Dias JA. Eosinophilic esophagitis: an emerging
disease in childhood - review of diagnostic and management
strategies. Front Pediatr. 2014;2:129.
Kelly KJ, Lazenby AJ, Rowe PC, et al. Eosinophilic esophagitis
attributed to gastroesophageal reflux: improvement with an
amino
acid-based
formula.
Gastroenterology.
1995;109:
1503–1512.
Markowitz JE, Spergel JM, Ruchelli E, et al. Elemental diet is an
effective treatment for eosinophilic esophagitis in children and
adolescents. Am J Gastroenterol. 2003;98:777–782.
Henderson CJ, Abonia JP, King EC, et al. Comparative dietary
therapy effectiveness in remission of pediatric eosinophilic
esophagitis. J Allergy Clin Immunol. 2012;129:1570–1578.
Peterson KA, Byrne KR, Vinson LA, et al. Elemental diet induces
histologic response in adult eosinophilic esophagitis. Am J
Gastroenterol. 2013;108:759–766.
Spergel JM, Andrews T, Brown-Whitehorn TF, et al. Treatment of
eosinophilic esophagitis with specific food elimination diet
directed by a combination of skin prick and patch tests. Ann
Allergy Asthma Immunol. 2005;95:336–343.
Eggesbo M, Botten G, Halvorsen R, et al. The prevalence of CMA/
CMPI in young children: the validity of parentally perceived reactions in a population-based study. Allergy. 2001;56:393–402.
Koletzko S, Niggemann B, Arato A, et al. Diagnostic approach and
management of cow’s-milk protein allergy in infants and children:
ESPGHAN GI Committee practical guidelines. J Pediatr
Gastroenterol Nutr. 2012;55:221–229.
Sicherer S. Epidemiology of food allergy. J Allergy Clin Immunol.
2011;127:594–602.
Rona RJ, Keil T, Summers C, et al. The prevalence of food allergy:
a meta-analysis. J Allergy Clin Immunol. 2007;120:638–646.
Kagalwalla AF, Sentongo TA, Ritz S, et al. Effect of six-food elimination diet on clinical and histologic outcomes in eosinophilic
esophagitis. Clin Gastroenterol Hepatol. 2006;4:1097–1102.
Gutierrez-Junquera C, Fernandez-Fernandez S, Cilleruelo ML, et al.
The role of proton pump inhibitors in the management of pediatric eosinophilic esophagitis. Front Pediatr. 2018;6:119.
[36]
[37]
[38]
[39]
[40]
[41]
[42]
[43]
[44]
[45]
[46]
[47]
[48]
[49]
[50]
[51]
[52]
[53]
[54]
[55]
[56]
Guti
errez-Junquera C, Fernandez-Fernandez S, Cilleruelo ML, et al.
Long-term treatment with proton pump inhibitors is effective in
children with eosinophilic esophagitis. J Pediatr Gastroenterol
Nutr. 2018;67:210–216.
Liacouras CA, Wenner WJ, Brown K, et al. Primary eosinophilic
esophagitis in children: successful treatment with oral corticosteroids. J Pediatr Gastroenterol Nutr. 1998;264:380–385.
Schaefer ET, Fitzgerald JF, Molleston JP, et al. Comparison of oral
prednisone and topical fluticasone in the treatment of eosinophilic esophagitis: a randomized trial in children. Clin
Gastroenterol Hepatol. 2008;6:165–173.
Dellon ES. Management of refractory eosinophilic oesophagitis.
Nat Rev Gastroenterol Hepatol. 2017;14:479–490.
Alexander JA, Ravi K, Enders FT, et al. Montelukast does not
maintain symptom remission after topical steroid therapy for
eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2017;15:
214–221.
Quan MN, Aceves SS. Medical and dietary management of
eosinophilic esophagitis. Ann Allergy Asthma Immunol. 2018;
121(2):156–161.
Markowitz JE, Jobe L, Miller M, et al. Safety and efficacy of reslizumab for children and adolescents with eosinophilic esophagitis
treated over nine years. J Pediatr Gastroenterol Nutr. 2018;66:
893–897.
Netzer P, Gschossman JM, Straumann A, et al. Corticosteroiddependent eosinophilic oesophagitis: azathioprine and 6-mercaptopurine can induce and maintain long-term remission. Eur J
Gastroenterol Hepatol. 2007;19:865–869.
Lieberman JA, Zhang J, Whitworth J, et al. A randomized, doubleblinded, placebo-controlled study of the use of viscous oral cromolyn sodium for the treatment of eosinophilic esophagitis. Ann
Allergy Asthma Immunol. 2018;120:527–531.
Constantine G, Seth N, Chokshi N, et al. Combination steroid and
test-based food elimination for eosinophilic esophagitis: a retrospective analysis. J Pediatr Gastroenterol Nutr. 2017;64:933–938.